异动解读 | Vir Biotechnology盘中大涨5.83%,T细胞吸引剂临床试验数据喜人

异动解读
10 Jan

在今日的交易中,Vir Biotechnology Inc.(VIR.O)股票盘中大涨5.83%,引发了市场的广泛关注。

此次股价上涨的主要原因是,该公司 T 细胞吸引剂(TCE)技术的早期临床试验数据令人鼓舞。该技术利用抗体靶向肿瘤细胞,同时激活T细胞,帮助免疫系统消灭癌细胞。

数据显示,VIR公司采用TCE技术开发的VIR-5818和VIR-5500药物在早期临床试验中,对多种实体瘤患者产生了令人信服的疗效反应。值得关注的是,这两种药物在治疗过程中未引起严重的细胞因子释放综合征,有望通过加大剂量和减少用药频率来提高疗效。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10